Laboratorio Farmaceutico Erfo SpA
MMIL:ERFO1.04
EUR
0.00
(0.00%)
Laboratorio Farmaceutico Erfo SpA
MIL:ERFO
(Euronext Milan)
Recent
price
1.04
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.- Similar Companies
- Business
- Laboratorio Farmaceutico Erfo SpA is an Italy-based nutraceutical and integrated wellness company that specializes in the research, formulation, industrial manufacturing, and commercialization of dietary supplements, specialized medical-grade nutraceuticals, and personalized health and fitness solutions. Founded in 2013 and headquartered in Villafranca Tirrena, Italy, the company operates as a certified Benefit Corporation (Società Benefit) and innovative SME across four core business segments: Diètnatural, BodySano, Medical Division, and Contract Development and Manufacturing (CDMO). Through its proprietary Diètnatural retail franchise network, Erfo provides personalized nutritional counseling and dietary monitoring; weight management supplements, detoxifying solutions, and metabolic boosters; functional foods, meal replacements, and dietary products; and herbal teas, infusions, and botanical extracts. Under the BodySano brand, the company delivers integrated aesthetic treatments, non-invasive body contouring, and nutritional rebalancing protocols. The company's Medical Division develops and distributes therapeutic nutraceutical products distributed through wholesale pharmaceutical channels, pharmacies, parapharmacies, and medical specialists, offering gastroenterology supplements such as Alginat Plus, Butiplus Repair, Procinetix Digestion, and Glusan Epato Detox; orthopedic and osteointegration formulations including Osteo-Therapy, Osteo-Protex, and Trianase Plus; vascular and microcirculation treatments such as Plusven Forte and Emorvia; urological and andrological formulations including Calcoless and Blue Performa; and neurological support products such as Mind 1000. Through its CDMO and private-label operations, Erfo provides third-party pharmaceutical and healthcare enterprises with end-to-end formulation development, regulatory consulting, quality control, packaging, and manufacturing services across dosage forms including tablets, hard capsules, single-dose sachets, stick packs, liquid vials, drops, and syrups. In addition, the company delivers high-tech fitness services featuring electro-myostimulation (EMS) and fast-fitness training sessions. Geographically, the company maintains operations across Italy, France, and Belgium, serving direct consumers, franchisees, healthcare professionals, and corporate B2B clients. In recent developments, Erfo executed a major strategic expansion in February 2025 by completing the acquisition of a 51 percent majority stake in Fit&Go S.r.l. for approximately 2.36 million euros, successfully integrating boutique high-tech fitness and EMS training centers into its corporate wellness platform. The company also expanded its therapeutic pipeline through the commercial launch of its patented Osteo-Therapy line developed in collaboration with academic institutions for dental and orthopedic bone regeneration, while continuing the European scale-up of its multi-brand retail and franchise network across more than 270 points of sale.